What is Enfusion Price-to-Operating-Cash-Flow?
As of today (2024-05-03), Enfusion's share price is $9.57.
Enfusion's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.20. Hence, Enfusion's Price-to-Operating-Cash-Flow Ratio for today is 47.85.
The historical rank and industry rank for Enfusion's Price-to-Operating-Cash-Flow or its related term are showing as below:
ENFN'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 35.41 Med: 46.51 Max: 266.74
Current: 47.51
During the past 5 years, Enfusion's highest Price-to-Operating-Cash-Flow Ratio was 266.74. The lowest was 35.41. And the median was 46.51.
Enfusion's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $0.05.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.20.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Enfusion was 19.30% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 96.70% per year.
During the past 5 years, Enfusion's highest 3-Year average Operating Cash Flow per Share Growth Rate was 96.70% per year. The lowest was -4.70% per year. And the median was 46.00% per year.
Enfusion Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Enfusion's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enfusion Price-to-Operating-Cash-Flow Chart
|
Enfusion Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
- |
- |
- |
58.25 |
48.99 |
|
Enfusion Quarterly Data
|
|
Dec19 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
58.25 |
56.45 |
56.67 |
38.50 |
48.99 |
Competitive Comparison of Enfusion's Price-to-Operating-Cash-Flow
For the Software - Application subindustry, Enfusion's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enfusion's Price-to-Operating-Cash-Flow Distribution in the Software Industry
For the Software industry and Technology sector, Enfusion's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Enfusion's Price-to-Operating-Cash-Flow falls into.
Enfusion Price-to-Operating-Cash-Flow Calculation
Enfusion's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 9.57 | / | 0.2 |
| = | 47.85 |
Enfusion's Share Price of today is $9.57.
Enfusion's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Enfusion (Enfusion) Business Description
Traded in Other Exchanges
N/A
Address
125 South Clark Street, Suite 750, Chicago, IL, USA, 60603
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.
Executives
| Deirdre Somers |
director |
C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603 |
| Bradley Herring |
officer: Chief Financial Officer |
C/O SHIFT4 PAYMENTS, INC., 2202 N. IRVING STREET, ALLENTOWN PA 16109 |
| Oleg Movchan |
director, 10 percent owner |
C/O ENFUSION INC., 125 SOUTH CLARK ST. STE 750, CHICAGO IL 60603 |
| Bronwen Bastone |
officer: Chief People Officer |
C/O ENFUSION, INC., 125 SOUTH CLARK STREET SUITE 750, CHICAGO IL 60603 |
| Stephen Malherbe |
10 percent owner |
C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603 |
| Dan Groman |
officer: Chief Technology Officer |
C/O ENFUSION INC., 125 SOUTH CLARK STREET STE. 750, CHICAGO IL 60603 |
| Tarek Hammoud |
10 percent owner |
C/O ENFUSION INC., 125 SOUTH CLARK ST. STE. 750, CHICAGO IL 60603 |
| Ftv Investment Holdings, L.p. |
10 percent owner |
601 CALIFORNIA STREET, FLOOR 19, SAN FRANCISCO CA 94108 |
| Michael Spellacy |
director |
399 PARK AVENUE, NEW YORK NY 10022 |
| Quiet Light Securities, Llc |
10 percent owner |
70 WEST MADISON, SUITE 1675, CHICAGO IL 60602 |
| Steven M. Bachert |
officer: Chief Revenue Officer |
C/O ENFUSION INC., 125 SOUTH CLARK ST., STE 750, CHIGAGO IL 60603 |
| Lra Ventures, Llc |
10 percent owner |
C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603 |
| Hillhouse Investment Management, Ltd. |
10 percent owner |
OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006 |
| Roy Luo |
director |
394 PACIFIC AVENUE, 2ND FLOOR, SAN FRANCISCO CA 94111 |
| Iconiq Strategic Partners V-b, L.p. |
10 percent owner |
394 PACIFIC AVENUE, SECOND FLOOR, SAN FRANCISCO CA 94111 |
Enfusion (Enfusion) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENFN has been successfully added to your